Abstract
It is well accepted that acetylcholine is involved in memory and learning processes and that loss of memory is characteristic of Alzheimers disease (AD). Several muscarinic agonists have been shown to be clinically effective in the treatment of AD. However, their use has been limited due to adverse side effects. As a result, more selective M1 agonists are expected to be the next generation of agents for the treatment of AD. One pharmacological approach to evaluate possible cognitive effects of compounds includes their ability to reverse scopolamine-induced amnesia. In the current study the succinamide and succinimide of p-aminophenol, two newly synthesized compounds that were previously designed to be acetylcholine analogues, were evaluated in a Pavlovian/Instrumental autoshaped memory task. Simultaneously, docking studies on the M1 receptor were done. The scopolamine-induced amnesia was reversed by the amide but not the imide. These findings are in line with results derived from the docking simulations, and suggest that at least the succinamide of p-aminophenol could represent a novel candidate for the treatment of AD.
Keywords: Succinic acid, p-aminophenol, scopolamine, allosteric, docking simulations, Alzheimer's disease, memory
Medicinal Chemistry
Title: Effect of a M1 Allosteric Modulator on Scopolamine-Induced Amnesia
Volume: 3 Issue: 1
Author(s): J. Espinosa-Raya, M. Espinoza-Fonseca, O. Picazo and J. Trujillo-Ferrara
Affiliation:
Keywords: Succinic acid, p-aminophenol, scopolamine, allosteric, docking simulations, Alzheimer's disease, memory
Abstract: It is well accepted that acetylcholine is involved in memory and learning processes and that loss of memory is characteristic of Alzheimers disease (AD). Several muscarinic agonists have been shown to be clinically effective in the treatment of AD. However, their use has been limited due to adverse side effects. As a result, more selective M1 agonists are expected to be the next generation of agents for the treatment of AD. One pharmacological approach to evaluate possible cognitive effects of compounds includes their ability to reverse scopolamine-induced amnesia. In the current study the succinamide and succinimide of p-aminophenol, two newly synthesized compounds that were previously designed to be acetylcholine analogues, were evaluated in a Pavlovian/Instrumental autoshaped memory task. Simultaneously, docking studies on the M1 receptor were done. The scopolamine-induced amnesia was reversed by the amide but not the imide. These findings are in line with results derived from the docking simulations, and suggest that at least the succinamide of p-aminophenol could represent a novel candidate for the treatment of AD.
Export Options
About this article
Cite this article as:
Espinosa-Raya J., Espinoza-Fonseca M., Picazo O. and Trujillo-Ferrara J., Effect of a M1 Allosteric Modulator on Scopolamine-Induced Amnesia, Medicinal Chemistry 2007; 3 (1) . https://dx.doi.org/10.2174/157340607779317526
DOI https://dx.doi.org/10.2174/157340607779317526 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Inflammatory Risk Factors and Pathologies Associated with Alzheimers Disease
Current Alzheimer Research Dogs with Cognitive Dysfunction Syndrome: A Natural Model of Alzheimer’s Disease
Current Alzheimer Research Changes in Cannabinoid Receptor Subtype 1 Activity and Interaction with Metabotropic Glutamate Subtype 5 Receptors in the Periaqueductal Gray- Rostral Ventromedial Medulla Pathway in a Rodent Neuropathic Pain Model
CNS & Neurological Disorders - Drug Targets Opioids: Other Routes for Use in Recovery Room
Current Drug Targets Adolescent Pregnancy and Parenting
Current Psychiatry Reviews Benzimidazole Derivatives as Centerally Acting Agents
Current Drug Therapy Cardiac Autonomic Nervous System in Heart Failure: Imaging Technique and Clinical Implications
Current Cardiology Reviews Clinical Application of Lentiviral Vectors – Concepts and Practice
Current Gene Therapy Comparison of the Effects of Dexamethasone and Ondansetron on the Reduction of Postoperative Nausea and Vomiting following Cesarean Section under Spinal Anesthesia
Current Reviews in Clinical and Experimental Pharmacology Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Erratum
Current Alzheimer Research Editorial (Is there a Need for Safety Monitoring Guidelines for Antidepressant Treatment?)
Current Drug Safety Non-Analgesic Effects of Opioids: The Interaction of Opioids with Bone and Joints
Current Pharmaceutical Design Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma
Current Medicinal Chemistry miR-7 Replacement Therapy in Parkinson’s Disease
Current Gene Therapy Pharmacological and Toxicological Profile of Harmane-β-Carboline Alkaloid: Friend or Foe
Current Drug Metabolism Stem Cell and Gene Therapeutic Strategies for the Treatment of Multiple Sclerosis
Current Molecular Medicine